Sponsor content
217 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OCREVUS SC ocrelizumab 920 mg/23 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 3 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 9 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Medication transfer set.
-
Australian public assessment report (AusPar)ITOVEBI (inavolisib), in combination with palbociclib and fulvestrant, is for the treatment of adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy.
-
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VABYSMO faricimab 120 mg/mL solution for injection in a pre-filled syringe.
-
-
Australian public assessment report (AusPar)Columvi (glofitamab), with obinutuzumab pretreatment, was provisionally approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Columvi is not indicated for the treatment of patients with primary central nervous system lymphoma.